Surveillance for cholangiocarcinoma in PSC: MRI, ERCP, both—or neither?
Exploration of Digestive Diseases · 2025
DOI: 10.37349/edd.2025.1005102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Digestive Diseases, 2025. Verfasst von Vincenzo Giorgio Mirante. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is an aggressive malignancy, accounting for around 15% of all primary hepatic tumours.It often presents at an advanced stage and has a poor prognosis [1].Identifying high-risk populations and implementing effective surveillance strategies are, therefore, priorities in hepatobiliary oncology.High-risk groups for CCA include individuals with primary sclerosing cholangitis (PSC), choledochal cysts, cirrhosis, chronic hepatitis B or C infection, and metabolic/behavioral factors such as obesity, harmful alcohol use, and tobacco smoking [2].Among these, PSC confers the highest lifetime risk of CCA and is also associated with smaller increases in gallbladder and hepatocellular cancers.Current society guidelines broadly endorse surveillance in adults with PSC, but the optimal modality and interval remain unsettled, and practice patterns vary widely across centers [3][4][5].
Zitieren
APA
Mirante, V. G. (2025). Surveillance for cholangiocarcinoma in PSC: MRI, ERCP, both—or neither?. Exploration of Digestive Diseases. https://doi.org/10.37349/edd.2025.1005102
Vancouver
Mirante VG. Surveillance for cholangiocarcinoma in PSC: MRI, ERCP, both—or neither?. Exploration of Digestive Diseases. 2025. doi:10.37349/edd.2025.1005102
BibTeX
@article{Mirante2025,
author = {Mirante, Vincenzo Giorgio},
title = {Surveillance for cholangiocarcinoma in PSC: MRI, ERCP, both—or neither?},
journal = {Exploration of Digestive Diseases},
year = {2025},
doi = {10.37349/edd.2025.1005102}
}
EUVIMED